kabutan

ONO PHARMACEUTICAL CO., LTD.(4528) Summary

4528
TSE Prime
ONO PHARMACEUTICAL CO., LTD.
2,103.0
JPY
-38.5
(-1.80%)
Dec 5, 3:30 pm JST
13.60
USD
Dec 5, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
14.7
PBR
1.23
Yield
3.80%
Margin Trading Ratio
11.36
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
2,137.0 JPY 13.77 USD
Previous Close Dec 4
2,141.5 JPY 13.78 USD
High Dec 5, 9:00 am
2,139.0 JPY 13.78 USD
Low Dec 5, 3:24 pm
2,096.5 JPY 13.55 USD
Volume
2,010,200
Trading Value
4.25B JPY 0.03B USD
VWAP
2113.49 JPY 13.67 USD
Minimum Trading Value
210,300 JPY 1,360 USD
Market Cap
1.05T JPY 6.81B USD
Number of Trades
4,626
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
4,012
1-Year High Oct 9, 2025
12,294
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 119,500 925,300 7.74
Nov 21, 2025 148,300 824,500 5.56
Nov 14, 2025 133,700 812,200 6.07
Nov 7, 2025 119,200 757,600 6.36
Oct 31, 2025 137,700 858,300 6.23
Company Profile
ONO PHARMACEUTICAL CO., LTD. is a mid-tier pharmaceutical company known for its high ratio of in-house developed products, although many are nearing patent expiration. The company is experiencing growth with its new cancer drug "Opdivo".
Sector
Pharmaceuticals
ONO PHARMACEUTICAL CO., LTD. focuses primarily on prescription pharmaceuticals but also produces over-the-counter medications. The company emphasizes research and development, with a strength in innovative in-house products. It operates internationally through subsidiaries engaged in manufacturing, sales, clinical development, and in-licensing/out-licensing activities. The company has sales subsidiaries in Korea and Taiwan, and subsidiaries for clinical development and licensing activities in the United States and the United Kingdom. ONO has achieved significant success with its pioneering cancer immunotherapy drug "Opdivo". The company has also expanded into healthcare-related products, dental supplies, and digital health fields. ONO actively pursues innovation through acquisitions of pharmaceutical startups. The entire group operates under a single business segment of pharmaceuticals.